Improvement in Zebrafish with Diabetes and Alzheimer's Disease Treated with Pasteurized Akkermansia muciniphila

Qu, Linkai; Liu, Fan; Fang, Yimeng; Wang, Lei; Chen, Haojie; Yang, Qinsi; Dong, Hao; Jin, Libo; Wu, Wei; Sun, Da

doi:10.1128/spectrum.00849-23

Cited by 9 publications

(7 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is similar to a recent study that reported that the Icariin intervention significantly improved cognitive dysfunction in AD mice by elevating the abundance of Akkermansia and reducing the abundance of Mucispirillum. As a recognized next-generation probiotic, Akkermansia is closely related to the positive systemic effects on host metabolism and homeostatic immunity and significantly contributes to the progression of AD. , Akkermansia has been found to enhance the reduction of Aβ40–42 and ameliorate intestinal barrier dysfunction . Previous studies have suggested that Clostridium butyricum regulates gut homeostasis and induces IL-10-producing macrophages and response in anti-inflammatory; thus, it is a breakthrough in probiotics …”

Section: Discussionmentioning

confidence: 99%

Effect of Human Milk Oligosaccharides on Learning and Memory in Mice with Alzheimer’s Disease

Gao,

Fang,

Sun

et al. 2023

J. Agric. Food Chem.

View full text Add to dashboard Cite

Alzheimer's disease (AD) is distinguished by cognitive dysfunction and neuroinflammation in the brain. 2′-Fucosyllactose (2′-FL) is a major human milk oligosaccharide (HMO) that is abundantly present in breast milk and has been demonstrated to exhibit immunomodulatory effects. However, the role of 2′-FL and HMO in gut microbiota modulation in relation to AD remains insufficiently investigated. This study aimed to elucidate the preventive effect of the 2′-FL and HMO impact of AD and the relevant mechanism involved. Here, the behavioral results showed that 2′-FL and HMO intervention decreased the expression of Tau phosphorylation and amyloid-β (Aβ), inhibited neuroinflammation, and restored cognitive impairment in AD mice. The metagenomic analysis proved that 2′-FL and HMO intervention restored the dysbiosis of the gut microbiota in AD. Notably, 2′-FL and HMO intervention significantly enhanced the relative abundance of Clostridium and Akkermansia. The metabolomics results showed that 2′-FL and HMO enhanced the oleoyl-L-carnitine metabolism as potential drivers. More importantly, the levels of oleoyl-L-carnitine were positively correlated with the abundances of Clostridium and Akkermansia. These results indicated that 2′-FL and HMO had therapeutic potential to prevent AD-induced cognitive impairment, which is of great significance for the treatment of AD.

show abstract

Section: Discussionmentioning

confidence: 99%

Effect of Human Milk Oligosaccharides on Learning and Memory in Mice with Alzheimer’s Disease

Gao,

Fang,

Sun

et al. 2023

J. Agric. Food Chem.

View full text Add to dashboard Cite

show abstract

“…Akkermansia muciniphila ( A. muciniphila ) exhibited comparable functionalities, as evidenced by its significant amelioration of Aβ protein deposition and intestinal barrier dysfunction in the brains of APP/PS1 mice, and neurobehavioral assessments demonstrated notable enhancements in memory function and mitigation of obesity induced by a high-fat diet [ 108 , 109 ]. Subsequent investigations unveiled that pasteurized A. muciniphila yielded significantly superior outcomes in memory, anxiety, aggression, and social preference compared to untreated A. muciniphila [ 110 ]. By modulating gut microbiota, the authors also discovered that pasteurized A. muciniphila enhanced systemic metabolism and A protein deposition in the brain [ 110 ].…”

Section: Treatment Strategy Of Ad Based On Gut Microbiotamentioning

confidence: 99%

“…Subsequent investigations unveiled that pasteurized A. muciniphila yielded significantly superior outcomes in memory, anxiety, aggression, and social preference compared to untreated A. muciniphila [ 110 ]. By modulating gut microbiota, the authors also discovered that pasteurized A. muciniphila enhanced systemic metabolism and A protein deposition in the brain [ 110 ]. SLAB51 exhibited comparable efficacy to A. muciniphila in reducing blood glucose and lipids.…”

Section: Treatment Strategy Of Ad Based On Gut Microbiotamentioning

confidence: 99%

Microbiota-Gut-Brain Axis Dysregulation in Alzheimer's Disease: Multi-Pathway Effects and Therapeutic Potential

Qu,

Li,

Liu

et al. 2023

Aging and disease

Self Cite

View full text Add to dashboard Cite

An essential regulator of neurodegenerative conditions like Alzheimer's disease (AD) is the gut microbiota. Alterations in intestinal permeability brought on by gut microbiota dysregulation encourage neuroinflammation, central immune dysregulation, and peripheral immunological dysregulation in AD, as well as hasten aberrant protein aggregation and neuronal death in the brain. However, it is unclear how the gut microbiota transmits information to the brain and how it influences brain cognition and function. In this review, we summarized the multiple pathways involved in the gut microbiome in AD and provided detailed treatment strategies based on the gut microbiome. Based on these observations, this review also discusses the problems, challenges, and strategies to address current therapeutic strategies.

show abstract

“…AD is primarily characterized by a progressive decline in memory and cognitive functions, leading to a diminished capacity for daily activities[ 13 ]. Pathologically, AD is marked by the deposition of amyloid plaques in neurons and the formation of neurofibrillary tangles, both contributing to altered brain tissue structure and function[ 14 - 16 ]. Currently, AD diagnosis predominantly relies on clinical assessments and neuroimaging, but these methods have limitations, particularly in early detection and disease progression monitoring[ 1 , 17 , 18 ].…”

Section: Introductionmentioning

confidence: 99%

“…Currently, AD diagnosis predominantly relies on clinical assessments and neuroimaging, but these methods have limitations, particularly in early detection and disease progression monitoring[ 1 , 17 , 18 ]. Increasing evidence suggests that AD pathogenesis involves various factors, including neuroinflammation, immune dysregulation, and vascular dysfunction[ 14 ]. Consequently, identifying relevant biomarkers has become a crucial research focus.…”

Section: Introductionmentioning

confidence: 99%

Evaluating serum CXCL12, sCD22, Lp-PLA2 levels and ratios as biomarkers for diagnosis of Alzheimer's disease

Liu,

Hua,

et al. 2024

World J Psychiatry

View full text Add to dashboard Cite

BACKGROUND Grasping the underlying mechanisms of Alzheimer's disease (AD) is still a work in progress, and existing diagnostic techniques encounter various obstacles. Therefore, the discovery of dependable biomarkers is essential for early detection, tracking the disease's advancement, and steering treatment strategies. AIM To explore the diagnostic potential of serum CXCL12, sCD22, Lp-PLA2, and their ratios in AD, aiming to enhance early detection and inform targeted treatment strategies. METHODS The study was conducted in Dongying people's Hospital from January 2021 to December 2022. Participants included 60 AD patients (AD group) and 60 healthy people (control group). Using a prospective case-control design, the levels of CXCL12, sCD22 and Lp-PLA2 and their ratios were detected by enzyme-linked immunosorbent assay kit in the diagnosis of AD. The differences between the two groups were analyzed by statistical methods, and the corresponding ratio was constructed to improve the specificity and sensitivity of diagnosis. RESULTS Serum CXCL12 levels were higher in the AD group (47.2 ± 8.5 ng/mL) than the control group (32.8 ± 5.7 ng/mL, P < 0.001), while sCD22 levels were lower (14.3 ± 2.1 ng/mL vs 18.9 ± 3.4 ng/mL, P < 0.01). Lp-PLA2 levels were also higher in the AD group (112.5 ± 20.6 ng/mL vs 89.7 ± 15.2 ng/mL, P < 0.05). Significant differences were noted in CXCL12/sCD22 (3.3 vs 1.7, P < 0.001) and Lp-PLA2/sCD22 ratios (8.0 vs 5.2, P < 0.05) between the groups. Receiver operating characteristic analysis confirmed high sensitivity and specificity of these markers and their ratios in distinguishing AD, with area under the curves ranging from 0.568 to 0.787. CONCLUSION Serum CXCL12 and Lp-PLA2 levels were significantly increased, while sCD22 were significantly decreased, as well as increases in the ratios of CXCL12/sCD22 and Lp-PLA2/sCD22, are closely related to the onset of AD. These biomarkers and their ratios can be used as potential diagnostic indicators for AD, providing an important clinical reference for early intervention and treatment.

show abstract

Improvement in Zebrafish with Diabetes and Alzheimer's Disease Treated with Pasteurized Akkermansia muciniphila

Cited by 9 publications

References 51 publications

Effect of Human Milk Oligosaccharides on Learning and Memory in Mice with Alzheimer’s Disease

Effect of Human Milk Oligosaccharides on Learning and Memory in Mice with Alzheimer’s Disease

Microbiota-Gut-Brain Axis Dysregulation in Alzheimer's Disease: Multi-Pathway Effects and Therapeutic Potential

Evaluating serum CXCL12, sCD22, Lp-PLA2 levels and ratios as biomarkers for diagnosis of Alzheimer's disease

Contact Info

Product

Resources

About